ME-344: a synthetic small molecule antineoplastic based on the isoflavan ring structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 68026984 |
| SCHEMBL ID | 10073998 |
| MeSH ID | M000605810 |
| Synonym |
|---|
| me 344 [who-dd] |
| gtpl7961 |
| (3r,4s)-3,4-bis(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2h-chromen-7-ol |
| 1374524-68-1 |
| 2h-1-benzopyran-7-ol, 3,4-dihydro-3,4-bis(4-hydroxyphenyl)-8-methyl-, (3r,4s)- |
| 4,4'-(7-hydroxy-8-methylchroman-3,4-diyl)diphenol |
| me-344 |
| unii-843g0tdv51 |
| 843g0tdv51 , |
| SCHEMBL10073998 |
| DB13062 |
| 4,4'-((3r,4s)-7-hydroxy-8-methylchroman-3,4-diyl)diphenol |
| Q27083823 |
| DTXSID701031261 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The current phase 1, open-label, dose escalation study was conducted to establish the safety, tolerability, pharmacokinetic profile, and preliminary antitumor activity of the novel mitochondrial inhibitor ME-344 in patients with refractory solid tumors." | ( Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors. Bendell, JC; Burris, HA; Esquibel, V; Infante, JR; Jones, SF; Kurkjian, CD; Levin, W; Moore, KN; Moreno, O; Pant, S; Patel, MR, 2015) | 0.83 |
| "8 µg/mL and the area under the concentration curve from time zero to infinity was 25." | ( Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors. Bendell, JC; Burris, HA; Esquibel, V; Infante, JR; Jones, SF; Kurkjian, CD; Levin, W; Moore, KN; Moreno, O; Pant, S; Patel, MR, 2015) | 0.65 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.88) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (28.57%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||